Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2025-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2024营业收入扣除情况表的鉴证报告
Regulatory Filings
2025-03-27 Chinese
2024年度独立董事述职报告（黄正明）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from a specific independent director of the company. It details the director's background, attendance at board and committee meetings, exercise of duties, communication with auditors and investors, and evaluation of company governance and financial reporting compliance. It also discusses personnel changes in senior management and board secretary appointments. The document is a detailed report on the independent director's activities and oversight during the year, focusing on governance and compliance rather than financial results or earnings. It is not an annual report, audit report, earnings release, or regulatory filing. It fits best under Board/Management Information (MANG) because it reports on board-level activities, director duties, and management changes. The document length (5286 characters) and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2025-03-27 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-03-27 Chinese
2024业绩承诺审核报告
Regulatory Filings
2025-03-27 Chinese
公司商誉减值制度
Governance Information Classification · 95% confidence The document is a detailed internal control system for goodwill impairment testing of Qidi Pharmaceutical Group Co., Ltd. It outlines accounting policies, procedures, and disclosure requirements related to goodwill impairment in accordance with accounting standards and regulatory rules. It is a governance and accounting policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but focuses on internal control and accounting treatment standards. Therefore, it fits best under Governance Information (CGR), which covers reports detailing internal rules and governance practices.
2025-03-27 Chinese
关于2025年度对外担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's expected external guarantee limits for the year 2025. It includes information about the subsidiaries being guaranteed, the amounts, financial data of the subsidiaries, internal decision procedures, board opinions, and risk disclosures. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about financing guarantees, which relates to capital or financing updates. The document is substantive and not merely a brief notice or certification. Therefore, it fits best under Capital/Financing Update (CAP).
2025-03-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.